Clinical Study
Stem Cell Therapy for Corneal Epithelium Regeneration following Good Manufacturing and Clinical Procedures
Table 1
Preoperative data and outcomes at 12 months of 20 eyes with ocular surface failure due to limbal stem cell deficiency syndrome (LSCD) subjected to cultivated limbal epithelial transplantation (CLET).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Group 1: chemical injuries, Group 2: immune-based inflammatory diseases, Group 3: noninflammatory diseases; †T: total, S: severe; ‡visual potential: 1, improvement with CLET only (corneal opacity was only superficial); 2, improvement with one surgery different from corneal transplant after CLET (i.e., cataract removal); 3, improvement with subsequent corneal transplant after CLET (corneal opacity was full thickness); 4, improvement with subsequent corneal transplant plus another surgery (cataract removal unless otherwise specified) after CLET, and 0: no possibility of improvement (i.e., due to irreversible retinal pathology). Auto-, autologous; Allo-, allogeneic; BCVA, best corrected visual acuity; BCVA values 0.01, 0.001, 0.0001, and 0.00001 equivalent to counting fingers, hand motion, light perception, and no light perception, respectively; Conj, conjunctival; Fluor, fluorescein staining; IQR, interquartile range; IVCM, in vivo confocal microscopy; MP, mucous membrane pemphigoid; NEI-VFQ-25, National Eye Institute-Visual Function Questionnaire; OSDI, ocular surface disease index; SPK, superficial punctate keratitis; PED, persistent epithelial defect; PKP, penetrating keratoplasty; and SD, standard deviation. |